GB0005700D0 - Therapy - Google Patents

Therapy

Info

Publication number
GB0005700D0
GB0005700D0 GBGB0005700.0A GB0005700A GB0005700D0 GB 0005700 D0 GB0005700 D0 GB 0005700D0 GB 0005700 A GB0005700 A GB 0005700A GB 0005700 D0 GB0005700 D0 GB 0005700D0
Authority
GB
United Kingdom
Prior art keywords
dependence
therapy
antagonist
tolerance
nervosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0005700.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9887294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0005700(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0005700.0A priority Critical patent/GB0005700D0/en
Publication of GB0005700D0 publication Critical patent/GB0005700D0/en
Priority to DE60103384T priority patent/DE60103384T2/de
Priority to PCT/GB2001/001058 priority patent/WO2001066113A1/en
Priority to AT01910051T priority patent/ATE267013T1/de
Priority to CA002402341A priority patent/CA2402341A1/en
Priority to DK01910051T priority patent/DK1267869T3/da
Priority to NZ521228A priority patent/NZ521228A/en
Priority to HK03104297.9A priority patent/HK1053262B/en
Priority to AU37634/01A priority patent/AU783869B2/en
Priority to CN01808891A priority patent/CN1427720A/zh
Priority to EP01910051A priority patent/EP1267869B1/en
Priority to PT01910051T priority patent/PT1267869E/pt
Priority to TR2004/01862T priority patent/TR200401862T4/xx
Priority to US10/221,128 priority patent/US20030195139A1/en
Priority to JP2001564765A priority patent/JP2003525902A/ja
Priority to ES01910051T priority patent/ES2220727T3/es
Priority to SE01910051T priority patent/SE1267869T5/xx
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fertilizers (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
GBGB0005700.0A 2000-03-09 2000-03-09 Therapy Ceased GB0005700D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB0005700.0A GB0005700D0 (en) 2000-03-09 2000-03-09 Therapy
SE01910051T SE1267869T5 (cg-RX-API-DMAC10.html) 2000-03-09 2001-03-09
ES01910051T ES2220727T3 (es) 2000-03-09 2001-03-09 Antagonistas del receptor metabotropico de glutamato para tratar la tolerancia y la dependencia.
HK03104297.9A HK1053262B (en) 2000-03-09 2001-03-09 Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance
EP01910051A EP1267869B1 (en) 2000-03-09 2001-03-09 Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance
AT01910051T ATE267013T1 (de) 2000-03-09 2001-03-09 Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit
CA002402341A CA2402341A1 (en) 2000-03-09 2001-03-09 Metabotropic glutamate receptor antagonists for treating tolerance and dependency
DK01910051T DK1267869T3 (da) 2000-03-09 2001-03-09 Metabotrope glutamatreceptorantagonister til behandling af tolerance og afhængighed
NZ521228A NZ521228A (en) 2000-03-09 2001-03-09 Metabotropic glutamate receptor antagonists for treating tolerance and dependency
DE60103384T DE60103384T2 (de) 2000-03-09 2001-03-09 Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit
AU37634/01A AU783869B2 (en) 2000-03-09 2001-03-09 Metabotropic glutamate receptor antagonists for treating tolerance and dependency
CN01808891A CN1427720A (zh) 2000-03-09 2001-03-09 用于治疗耐受性和依赖性的促代谢谷氨酸受体拮抗剂
PCT/GB2001/001058 WO2001066113A1 (en) 2000-03-09 2001-03-09 Metabotropic glutamate receptor antagonists for treating tolerance and dependency
PT01910051T PT1267869E (pt) 2000-03-09 2001-03-09 Antogonistas de receptor de glutamato metabotropico para o tratamento de tolerancia e de dependencia
TR2004/01862T TR200401862T4 (tr) 2000-03-09 2001-03-09 Tolerans ve bağımlılığı tedavi etmek için metabotropik glutamat reseptör antagonistleri.
US10/221,128 US20030195139A1 (en) 2000-03-09 2001-03-09 Metabotropic glutamate receptor antagonists for treating tolerance and dependency
JP2001564765A JP2003525902A (ja) 2000-03-09 2001-03-09 耐性および依存症を治療するための代謝共役型グルタミン酸受容体アンタゴニスト

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0005700.0A GB0005700D0 (en) 2000-03-09 2000-03-09 Therapy

Publications (1)

Publication Number Publication Date
GB0005700D0 true GB0005700D0 (en) 2000-05-03

Family

ID=9887294

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0005700.0A Ceased GB0005700D0 (en) 2000-03-09 2000-03-09 Therapy

Country Status (16)

Country Link
US (1) US20030195139A1 (cg-RX-API-DMAC10.html)
EP (1) EP1267869B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003525902A (cg-RX-API-DMAC10.html)
CN (1) CN1427720A (cg-RX-API-DMAC10.html)
AT (1) ATE267013T1 (cg-RX-API-DMAC10.html)
AU (1) AU783869B2 (cg-RX-API-DMAC10.html)
CA (1) CA2402341A1 (cg-RX-API-DMAC10.html)
DE (1) DE60103384T2 (cg-RX-API-DMAC10.html)
DK (1) DK1267869T3 (cg-RX-API-DMAC10.html)
ES (1) ES2220727T3 (cg-RX-API-DMAC10.html)
GB (1) GB0005700D0 (cg-RX-API-DMAC10.html)
NZ (1) NZ521228A (cg-RX-API-DMAC10.html)
PT (1) PT1267869E (cg-RX-API-DMAC10.html)
SE (1) SE1267869T5 (cg-RX-API-DMAC10.html)
TR (1) TR200401862T4 (cg-RX-API-DMAC10.html)
WO (1) WO2001066113A1 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314192A (pt) * 2002-09-10 2005-07-26 Novartis Ag Antagonistas de receptores de mglu para tratamento de distúrbios associados com receptores de mglu incluindo vìcio e depressão
ES2819303T3 (es) 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
WO2006121919A2 (en) * 2005-05-05 2006-11-16 Massachusetts Institute Of Technology Methods of treating obsessive compulsive disorder
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007035823A2 (en) * 2005-09-20 2007-03-29 Molecular Neuroimaging, Llc Partial mglur5 antagonists and methods of use thereof
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
US20130123254A1 (en) * 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
GB201312800D0 (en) 2013-07-17 2013-08-28 Heptares Therapeutics Ltd mGlu5 modulators
AU2018310882C1 (en) 2017-07-31 2021-12-09 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
KR20200035035A (ko) * 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
JP7620694B2 (ja) * 2020-07-17 2025-01-23 ノバルティス アーゲー オピオイド使用の低減用医薬品及びオピオイド禁断の促進用医薬品
CA3204360A1 (en) * 2020-12-14 2022-06-23 Novartis Ag Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5543698A (en) * 1994-09-27 1996-08-06 Allen-Bradley Company, Inc. Method and apparatus used with AC motor for detecting unbalance
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
US6294355B1 (en) * 1997-03-14 2001-09-25 The Johns Hopkins University School Of Medicine Synaptic activation protein compositions and method
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
ID29095A (id) * 1998-10-02 2001-07-26 Novartis Ag Cs Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
WO2000069816A1 (en) * 1999-05-17 2000-11-23 Eli Lilly And Company Metabotropic glutamate receptor antagonists
US6666209B2 (en) * 2001-02-20 2003-12-23 3M Innovative Properties Company Method and system of calibrating air flow in a respirator system

Also Published As

Publication number Publication date
CN1427720A (zh) 2003-07-02
AU3763401A (en) 2001-09-17
SE1267869T3 (cg-RX-API-DMAC10.html) 2004-08-31
AU783869B2 (en) 2005-12-15
ATE267013T1 (de) 2004-06-15
JP2003525902A (ja) 2003-09-02
NZ521228A (en) 2004-04-30
HK1053262A1 (en) 2003-10-17
CA2402341A1 (en) 2001-09-13
WO2001066113A1 (en) 2001-09-13
DE60103384T2 (de) 2005-06-16
US20030195139A1 (en) 2003-10-16
EP1267869A1 (en) 2003-01-02
PT1267869E (pt) 2004-10-29
ES2220727T3 (es) 2004-12-16
EP1267869B1 (en) 2004-05-19
TR200401862T4 (tr) 2004-10-21
DE60103384D1 (de) 2004-06-24
DK1267869T3 (da) 2004-09-20
SE1267869T5 (cg-RX-API-DMAC10.html) 2004-09-07

Similar Documents

Publication Publication Date Title
SE1267869T3 (cg-RX-API-DMAC10.html)
DE60205776D1 (en) Indolinon-derivative als protein-kinasehemmer
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
DK0901374T3 (da) Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
MY121136A (en) Novel heterocyclic sulfonamides.
MXPA03007140A (es) Derivados de carbolina.
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
NZ544591A (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
MXPA06001008A (es) Derivados de 3-amino croman y 2-amino tetralina.
ES2153337T1 (es) Inhibidores de raf-quinasa.
SG167664A1 (en) 2,4-pyrimidinediamine compounds and their uses
MXPA03009750A (es) Compuestos quimicos.
ATE296809T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE402149T1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
ATE305787T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
DE60015599D1 (de) 3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN
MXPA02009549A (es) Imidazopiridinas triciclicas.
NO20003387L (no) FremgangsmÕte for Õ redusere aox-nivÕet av vÕtstyrkeharpikser ved behandling med base
SI1377574T1 (cg-RX-API-DMAC10.html)
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
AU2002322396A1 (en) 1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists
NO20033401D0 (no) Kjemiske forbindelser

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)